RUNX1 and acute lymphoblastic leukemia: Many genomic lesions in precursor B-cell acute lymphoblastic leukaemia (pre-B-ALL) are associated with alterations of cytokine receptors or their signalling pathway mediators, transcription factors or regulators of differentiation.1,2 These lesions have prognostic significance, for example, ETV6-RUNX1 is associated with a relatively favourable outcome compared with poor-risk disease associated with BCR-ABL+ (Philadelphia-positive (Ph+)) or Ph-like ALL.